Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.

Meet Our Team

A combined 150+ years of experience in the healthcare industry.

learn more

See Our Portfolio

$1.8 billion in assets, with a track record of investing and returning capital since 2000.

learn more

Latest News

Synergy Pharmaceuticals provides update on ongoing FDA review of plecanatide CIC NDA and IBS-C clinical development program

July 15, 2016
NEW YORK-- Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced it has reached the Food and Drug Administration (FDA) mid-cycle review milestone for the plecanatide new drug application (NDA) in chronic idiopathic…
READ MORE

Loxo Oncology Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-101

July 13, 2016
STAMFORD, Conn., July 13, 2016 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced…
READ MORE

CoolSculpting(R) by ZELTIQ(R) Receives Approval From China Food and Drug Administration for Fat Reduction

July 13, 2016
PLEASANTON, CA -- (Marketwired) -- 07/13/16 -- ZELTIQ® Aesthetics, Inc. (NASDAQ: ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology, today announced that…
READ MORE